Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Stock analysts at Oppenheimer increased their FY2023 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Tuesday, June 4th, according to Zacks Investment Research. Oppenheimer analyst M. Breidenbach now forecasts that the biopharmaceutical company will earn $1.91 per share for the year, up from their previous forecast of $1.75.
AGIO has been the subject of a number of other research reports. BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Cowen reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Wednesday, March 13th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 25th. Finally, Piper Jaffray Companies cut their price target on shares of Agios Pharmaceuticals from $100.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $86.14.
NASDAQ AGIO opened at $50.78 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.86 and a current ratio of 6.89. Agios Pharmaceuticals has a 1 year low of $41.63 and a 1 year high of $98.72. The firm has a market capitalization of $2.98 billion, a P/E ratio of -8.42 and a beta of 2.33.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.15. Agios Pharmaceuticals had a negative return on equity of 48.19% and a negative net margin of 300.63%. The firm had revenue of $30.20 million for the quarter, compared to the consensus estimate of $22.69 million. During the same period in the prior year, the firm earned ($1.63) EPS. The firm’s revenue was up 243.2% on a year-over-year basis.
In related news, insider Christopher Bowden sold 10,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $66.57, for a total transaction of $665,700.00. Following the completion of the transaction, the insider now owns 17,238 shares of the company’s stock, valued at approximately $1,147,533.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $67.71, for a total transaction of $203,130.00. Following the transaction, the insider now directly owns 29,511 shares of the company’s stock, valued at approximately $1,998,189.81. The disclosure for this sale can be found here. 3.16% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of AGIO. Quantamental Technologies LLC acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth $28,000. Advisor Group Inc. increased its stake in Agios Pharmaceuticals by 33.1% in the fourth quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 297 shares during the period. ETF Managers Group LLC boosted its holdings in shares of Agios Pharmaceuticals by 15.7% in the fourth quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 216 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in Agios Pharmaceuticals by 481.6% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,280 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 2,716 shares in the last quarter. Finally, S&CO Inc. purchased a new stake in Agios Pharmaceuticals during the first quarter worth about $229,000.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.